Francesco Dazzi

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/8333425/publications.pdf

Version: 2024-02-01

169 papers	13,505 citations	23879 60 h-index	25230 113 g-index
192 all docs	192 docs citations	192 times ranked	15409 citing authors

#	Article	IF	Citations
1	CD14 positive cells accelerate hematopoietic stem cell engraftment. Bone Marrow Transplantation, 2022, 57, 942-948.	1.3	2
2	Pluripotent Stem Cell-Derived Hepatocytes Inhibit T Cell Proliferation In Vitro through Tryptophan Starvation. Cells, 2022, 11, 24.	1.8	6
3	Assessing the immunosuppressive activity of alginate-encapsulated mesenchymal stromal cells on splenocytes. Artificial Cells, Nanomedicine and Biotechnology, 2022, 50, 168-176.	1.9	0
4	Acute myeloid leukemia shapes the bone marrow stromal niche <i>in vivo</i>. Haematologica, 2021, 106, 865-870.	1.7	14
5	On minor histocompatibility antigens, mixed chimerism, and transplantation tolerance. American Journal of Transplantation, 2021, 21, 919-920.	2.6	2
6	Immunomodulatory Properties of Mesenchymal Stromal Cells: An Update. Frontiers in Cell and Developmental Biology, 2021, 9, 637725.	1.8	76
7	Mixed T cell lineage chimerism in acute leukemia/MDS using pre-emptive donor lymphocyte infusion strategyâ€"Is it prognostic?â€"a single-center retrospective study. Blood Cancer Journal, 2021, 11, 128.	2.8	8
8	Apoptosis in the Pancreatic Cancer Tumor Microenvironmentâ€"The Double-Edged Sword of Cancer-Associated Fibroblasts. Cells, 2021, 10, 1653.	1.8	10
9	Macrophages orchestrate the expansion of a proangiogenic perivascular niche during cancer progression. Science Advances, 2021, 7, eabg9518.	4.7	32
10	Human Mesenchymal Stromal Cells Engineered to Express Collagen VII Can Restore Anchoring Fibrils in Recessive Dystrophic Epidermolysis Bullosa Skin Graft Chimeras. Journal of Investigative Dermatology, 2020, 140, 121-131.e6.	0.3	13
11	Phase I/II open-label trial of intravenous allogeneic mesenchymal stromal cell therapy in adults with recessive dystrophic epidermolysis bullosa. Journal of the American Academy of Dermatology, 2020, 83, 447-454.	0.6	50
12	Persistence of Drug-Resistant Leukemic Stem Cells and Impaired NK Cell Immunity in CML Patients Depend on MIR300 Antiproliferative and PP2A-Activating Functions. Blood Cancer Discovery, 2020, 1, 48-67.	2.6	30
13	Mesenchymal Stromal Cells for Graft Versus Host Disease: Mechanism-Based Biomarkers. Frontiers in Immunology, 2020, 11, 1338.	2.2	60
14	The emergence of regenerative medicine in organ transplantation: 1st European Cell Therapy and Organ Regeneration Section meeting. Transplant International, 2020, 33, 833-840.	0.8	15
15	Immunoregulation in the Hematopoietic Stem Cell Niche. , 2020, , 69-77.		0
16	Bone Marrow Transplantation 1957-2019. Frontiers in Immunology, 2019, 10, 1246.	2.2	21
17	Comparison of human isogeneic Whartonâ€™s jelly MSCs and iPSC-derived MSCs reveals differentiation-dependent metabolic responses to IFNG stimulation. Cell Death and Disease, 2019, 10, 277.	2.7	12
18	Acute myeloid leukaemia niche regulates response to Lâ€asparaginase. British Journal of Haematology, 2019, 186, 420-430.	1.2	18

#	Article	IF	Citations
19	Is platelet gel safe enough for neutropenic patients?. Transfusion and Apheresis Science, 2019, 58, 190-191.	0.5	1
20	Apoptotic mesenchymal stromal cells induce prostaglandin E2 in monocytes: implications for the monitoring of mesenchymal stromal cell activity. Haematologica, 2019, 104, e438-e441.	1.7	45
21	Challenges for mesenchymal stromal cell therapies. Science Translational Medicine, 2019, 11, .	5.8	126
22	Mesenchymal stromal cells for acute graftâ€versusâ€host disease: response at 1Âweek predicts probability of survival. British Journal of Haematology, 2019, 185, 89-92.	1.2	28
23	Mechanisms of Immune Resistance. , 2019, , 457-460.		0
24	Differential Alemtuzumab Dosage Effects in T-Cell Deplete Allogeneic Haematopoietic Stem Cell Transplants for Myeloid Malignancies- King's College Hospital London Experience. Blood, 2019, 134, 4622-4622.	0.6	0
25	Immune monitoring in allogeneic hematopoietic stem cell transplant recipients: a survey from the EBMT-CTIWP. Bone Marrow Transplantation, 2018, 53, 1201-1205.	1.3	10
26	Hematopoietic stem cell transplantation in its 60s: A platform for cellular therapies. Science Translational Medicine, 2018, 10, .	5.8	125
27	Mesenchymal-myeloid interaction in the regulation of immunity. Seminars in Immunology, 2018, 35, 59-68.	2.7	39
28	Repurposing Tin Mesoporphyrin as an Immune Checkpoint Inhibitor Shows Therapeutic Efficacy in Preclinical Models of Cancer. Clinical Cancer Research, 2018, 24, 1617-1628.	3.2	44
29	Advances in mesenchymal stromal cell therapy in the management of Crohnâ€™s disease. Expert Review of Gastroenterology and Hepatology, 2018, 12, 141-153.	1.4	20
30	Bi-directional cell-pericellular matrix interactions direct stem cell fate. Nature Communications, 2018, 9, 4049.	5.8	90
31	Multiparametric Analysis of Circulating Exosomes and Other Small Extracellular Vesicles by Advanced Imaging Flow Cytometry. Frontiers in Immunology, 2018, 9, 1583.	2.2	108
32	Manufacturing Mesenchymal Stromal Cells for the Treatment of Graft-versus-Host Disease: A Survey among Centers Affiliated with the European Society for Blood and Marrow Transplantation. Biology of Blood and Marrow Transplantation, 2018, 24, 2365-2370.	2.0	61
33	Repurposing tin mesoporphyrin as a novel immune checkpoint therapy in the treatment of cancer: A preclinical evaluation.. Journal of Clinical Oncology, 2018, 36, e15129-e15129.	0.8	0
34	Abstract 1134: The tumor suppressor activity of miR-300 is detrimental for leukemia development but required for leukemia stem cell maintenance. , 2018, , .		0
35	Monomeric, porous type II collagen scaffolds promote chondrogenic differentiation of human bone marrow mesenchymal stem cells in vitro. Scientific Reports, 2017, 7, 43519.	1.6	76
36	Bone marrow mesenchymal stromal cells induce nitric oxide synthase-dependent differentiation of CD11b + cells that expedite hematopoietic recovery. Haematologica, 2017, 102, 818-825.	1.7	16

#	Article	IF	Citations
37	Complement C3 Exacerbates Imiquimod-Induced Skin Inflammation andÂPsoriasiform Dermatitis. Journal of Investigative Dermatology, 2017, 137, 760-763.	0.3	16
38	Preclinical imaging methods for assessing the safety and efficacy of regenerative medicine therapies. Npj Regenerative Medicine, 2017, 2, 28.	2.5	47
39	Effects of maternal obesity on Whartonâ€™s Jelly mesenchymal stromal cells. Scientific Reports, 2017, 7, 17595.	1.6	8
40	Apoptosis in mesenchymal stromal cells induces in vivo recipient-mediated immunomodulation. Science Translational Medicine, 2017, 9, .	5.8	512
41	Human aplastic anaemiaâ€derived mesenchymal stromal cells form functional haematopoietic stem cell niche in vivo. British Journal of Haematology, 2017, 179, 669-673.	1.2	14
42	Roadmap to clinical translation: insights from a UK regenerative medicine platform workshop on mesenchymal stromal cells. Regenerative Medicine, 2017, 12, 895-897.	0.8	1
43	Immune Tolerance in Hemopoietic Stem Cell Transplantation. , 2016, , 241-247.		0
44	Rapid and Efficient Stable Gene Transfer to Mesenchymal Stromal Cells Using a Modified Foamy Virus Vector. Molecular Therapy, 2016, 24, 1227-1236.	3.7	10
45	International Society for Cellular Therapy perspective on immune functional assays for mesenchymal stromal cells as potency release criterion for advanced phase clinical trials. Cytotherapy, 2016, 18, 151-159.	0.3	400
46	Mesenchymal stem cells enhance bacterial clearance of streptococcalpneumoniae and pseudomonasaeruginosain the lung. , 2016, , .		0
47	How to Monitor Immune Reconstitution Following Allogeneic Hematopoietic Stem Cell Transplantation: A Survey from the EBMT- Cellular Therapy & Immunobiology Working Party. Blood, 2016, 128, 4581-4581.	0.6	0
48	Manufacturing of Mesenchymal Stromal Cells for the Treatment of Graft-Versus-Host Disease: A Survey within the European Society of Blood and Marrow Transplantation. Blood, 2016, 128, 3374-3374.	0.6	0
49	Hematopoietic mobilization. Neurology, 2015, 84, 1473-1482.	1.5	27
50	Umbilical Cord as a Source of Immunomodulatory Reagents. , 2015, , 125-140.		1
51	Classification and biology of tumour associated stromal cells. Immunology Letters, 2015, 168, 175-182.	1.1	34
52	Wharton's jelly mesenchymal stromal/stem cells derived under chemically defined animal product-free low oxygen conditions are rich in MSCA-1⁺ subpopulation. Regenerative Medicine, 2014, 9, 723-732.	0.8	14
53	Prophylaxis and treatment of GVHD: EBMTâ€“ELN working group recommendations for a standardized practice. Bone Marrow Transplantation, 2014, 49, 168-173.	1.3	252
54	Unique Regulatory Properties of Mesangial Cells Are Genetically Determined in the Rat. PLoS ONE, 2014, 9, e111452.	1.1	4

#	Article	IF	Citations
55	MSCs: science and trials. Nature Medicine, 2013, 19, 812-813.	15.2	26
56	Mesenchymal stromal cells and regulatory T cells: the Yin and Yang of peripheral tolerance?. Immunology and Cell Biology, 2013, 91, 12-18.	1.0	108
57	Escalating-dose HLA-mismatched DLI is safe for the treatment of leukaemia relapse following alemtuzumab-based myeloablative allo-SCT. Bone Marrow Transplantation, 2013, 48, 1324-1328.	1.3	11
58	Donor lymphocyte infusions for the treatment of chronic myeloid leukemia relapse following peripheral blood or bone marrow stem cell transplantation. Bone Marrow Transplantation, 2013, 48, 837-842.	1.3	8
59	Enhanced and aberrant <scp>T</scp> cell trafficking following total body irradiation: a gateway to graftâ€versusâ€host disease?. British Journal of Haematology, 2013, 162, 808-818.	1.2	9
60	Combined Inhibition of p97 and the Proteasome Causes Lethal Disruption of the Secretory Apparatus in Multiple Myeloma Cells. PLoS ONE, 2013, 8, e74415.	1.1	45
61	Acute myeloid leukemia creates an arginase-dependent immunosuppressive microenvironment. Blood, 2013, 122, 749-758.	0.6	249
62	Cancer makes new friends with old tricks. Blood, 2013, 122, 1093-1094.	0.6	5
63	The Immunosuppressive Properties of Adult Stem Cells: Mesenchymal Stem Cells as a Case Study. , 2013, , 175-197.		0
64	Clinical Perspectives of Mesenchymal Stem Cells. Stem Cells International, 2012, 2012, 1-3.	1.2	16
65	Mesenchymal stromal cells (MSC) for treating immune-mediated inflammation post-transplantation and in autoimmunity. The Cochrane Library, 2012, , .	1.5	2
66	Mesenchymal stromal cells: a key player in â€˜innate toleranceâ€™?. Immunology, 2012, 137, 206-213.	2.0	71
67	Graft invariant natural killer T-cell dose predicts risk of acute graft-versus-host disease in allogeneic hematopoietic stem cell transplantation. Blood, 2012, 119, 5030-5036.	0.6	129
68	EBMT Risk Score Predicts Outcome of Allogeneic Hematopoietic Stem Cell Transplantation in Patients Who Have Failed a Previous Transplantation Procedure. Biology of Blood and Marrow Transplantation, 2012, 18, 235-240.	2.0	25
69	Regulatory T cells in stem cell transplantation: Main characters or walk-on actors?. Critical Reviews in Oncology/Hematology, 2012, 84, 18-25.	2.0	8
70	Can Targeted Therapy for CML Still Learn From Transplant? Using Post-transplant RQ-PCR monitoring to Clarify the Importance of the Depth of Molecular Remission On the Risk of Subsequent Relapse.. Blood, 2012, 120, 2789-2789.	0.6	0
71	Minimally manipulated whole human umbilical cord is a rich source of clinical-grade human mesenchymal stromal cells expanded in human platelet lysate. Cytotherapy, 2011, 13, 786-801.	0.3	104
72	Mesenchymal stem cells and autoimmune diseases. Best Practice and Research in Clinical Haematology, 2011, 24, 49-57.	0.7	100

#	Article	IF	Citations
73	Regulatory T cell therapy for the induction of clinical organ transplantation tolerance. Seminars in Immunology, 2011, 23, 453-461.	2.7	20
74	Inhibition of osteoclast function reduces hematopoietic stem cell numbers in vivo. Blood, 2011, 117, 1540-1549.	0.6	119
75	The immunomodulatory properties of mesenchymal stem cells. Seminars in Immunopathology, 2011, 33, 593-602.	2.8	158
76	Efficacy of tyrosine kinase inhibitors (TKIs) as third-line therapy in patients with chronic myeloid leukemia in chronic phase who have failed 2 prior lines of TKI therapy. Blood, 2010, 116, 5497-5500.	0.6	65
77	Haemopoietic stem cell transplantation induces tolerance to donor antigens but not to foreign FVIII peptides. Haemophilia, 2010, 16, 143-147.	1.0	9
78	Effects of MSC co-injection on the reconstitution of aplastic anemia patient following hematopoietic stem cell transplantation. Leukemia, 2010, 24, 1791-1795.	3.3	26
79	Dasatinib may not suppress the GVL effect of donor lymphocyte infusions for CML. Bone Marrow Transplantation, 2010, 45, 395-396.	1.3	5
80	Outcome of patients developing GVHD after DLI given to treat CML relapse: a study by the chronic leukemia working party of the EBMT. Bone Marrow Transplantation, 2010, 45, 558-564.	1.3	56
81	The therapeutic activity of low-dose irradiation on experimental arthritis depends on the induction of endogenous regulatory T cell activity. Annals of the Rheumatic Diseases, 2010, 69, 1519-1526.	0.5	41
82	Bone marrow mesenchymal stromal cells non-selectively protect chronic myeloid leukemia cells from imatinib-induced apoptosis via the CXCR4/CXCL12 axis. Haematologica, 2010, 95, 1081-1089.	1.7	145
83	High Frequency and Cell Dose of Invariant NKT Cells In the Graft Are Associated with Lack of Clinically Significant Acute Gvhd In T Cell-Replete Sibling Allografts. Blood, 2010, 116, 2539-2539.	0.6	1
84	Mesenchymal stem cells and innate tolerance: biology and clinical applications. Swiss Medical Weekly, 2010, 140, w13121.	0.8	31
85	Response to Tyrosine Kinase Inhibitor Therapy In Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation for Advanced Phase Chronic Myeloid Leukemia. Blood, 2010, 116, 3515-3515.	0.6	0
86	Preconditioning Level of C-Reactive Protein and Disease Stage Are Key Prognostic Factors In Myeloablative Allogeneic Hematopoietic Stem Cell Transplantation.. Blood, 2010, 116, 3488-3488.	0.6	0
87	Mesenchymal stem cells: the fibroblasts' new clothes?. Haematologica, 2009, 94, 258-263.	1.7	303
88	The Immunosuppressive Properties of Mesenchymal Stem Cells. Transplantation, 2009, 87, S45-S49.	0.5	165
89	Longâ€term clinical results of autologous infusion of mobilized adult bone marrow derived CD34⁺ cells in patients with chronic liver disease. Cell Proliferation, 2008, 41, 115-125.	2.4	95
90	The highway code of T cell trafficking. Journal of Pathology, 2008, 214, 179-189.	2.1	88

#	Article	IF	Citations
91	Mesenchymal stem cells for graftâ€versusâ€host disease: Close encounters with T cells. European Journal of Immunology, 2008, 38, 1479-1482.	1.6	80
92	Mesenchymal stem cells for graft-versus-host disease: a double edged sword?. Leukemia, 2008, 22, 463-465.	3.3	35
93	The immunosuppressive effects of human bone marrow-derived mesenchymal stem cells target T cell proliferation but not its effector function. Cellular Immunology, 2008, 251, 131-136.	1.4	156
94	Chronic GVHD as an autoimmune disease. Best Practice and Research in Clinical Haematology, 2008, 21, 281-289.	0.7	47
95	127: Mesenchymal Stem Cells Exert Differential Effects on Alloantigen- and Virus-Specific T Cells. Biology of Blood and Marrow Transplantation, 2008, 14, 48-49.	2.0	0
96	Strontium can increase some osteoblasts without increasing hematopoietic stem cells. Blood, 2008, 111, 1173-1181.	0.6	113
97	Mesenchymal stem cells exert differential effects on alloantigen and virus-specific T-cell responses. Blood, 2008, 112, 532-541.	0.6	149
98	European LeukemiaNet criteria for failure or suboptimal response reliably identify patients with CML in early chronic phase treated with imatinib whose eventual outcome is poor. Blood, 2008, 112, 4437-4444.	0.6	293
99	Mesenchymal stem cell therapy for degenerative inflammatory disorders. Current Opinion in Organ Transplantation, 2008, 13, 639-644.	0.8	27
100	Dissection of Effector Pathways in the Host-Versus-Graft Response to Bone Marrow Transplantation. Transplantation, 2008, 86, 1311-1314.	0.5	0
101	Prediction of Cytogenetic Response to Second Generation TKI Therapy in CML Chronic Phase Patients Who Have Failed Imatinib Therapy and Early Identification of Factors That Influence Survival. Blood, 2008, 112, 332-332.	0.6	7
102	Allogeneic Myeloablative Hematopoietic Stem Cell Transplantation for Chronic Myelogenous Leukemia in the Imatinib Era.. Blood, 2008, 112, 970-970.	0.6	0
103	Osteoclast Function Is Essential in the Hematopoietic Stem Cell Niche. Blood, 2008, 112, 547-547.	0.6	0
104	The Antiproliferative Effect of Mesenchymal Stem Cells Is a Fundamental Property Shared by All Stromal Cells. Journal of Immunology, 2007, 179, 2824-2831.	0.4	231
105	Low-intensity transplant regimens facilitate recruitment of donor-specific regulatory T cells that promote hematopoietic engraftment. Proceedings of the National Academy of Sciences of the United States of America, 2007, 104, 8415-8420.	3.3	19
106	TCRÎ¶dimlymphocytes define populations of circulating effector cells that migrate to inflamed tissues. Blood, 2007, 109, 4328-4335.	0.6	47
107	Potential of mesenchymal stem cell therapy. Current Opinion in Oncology, 2007, 19, 650-655.	1.1	101
108	Mesenchymal Stem Cells Inhibit Dendritic Cell Differentiation and Function by Preventing Entry Into the Cell Cycle. Transplantation, 2007, 83, 71-76.	0.5	404

#	Article	IF	Citations
109	T-cell receptor repertoire usage after allografting differs between CD4+CD25+ regulatory T cells and their CD4+CD25 counterpart. Haematologica, 2007, 92, 206-214.	1.7	15
110	Cell therapy for autoimmune diseases. Arthritis Research and Therapy, 2007, 9, 206.	1.6	80
111	Immunomodulatory properties of mesenchymal stem cells: a review based on an interdisciplinary meeting held at the Kennedy Institute of Rheumatology Division, London, UK, 31 October 2005. Arthritis Research and Therapy, 2007, 9, 301.	1.6	150
112	Disease relapse after haematopoietic stem cell transplantation: Risk factors and treatment. Best Practice and Research in Clinical Haematology, 2007, 20, 311-327.	0.7	36
113	Mesenchymal stem cells inhibit proliferation and apoptosis of tumor cells: impact on in vivo tumor growth. Leukemia, 2007, 21, 304-310.	3.3	366
114	Increased frequencies of CD4+CD25high Tregs correlate with disease relapse after allogeneic stem cell transplantation for chronic myeloid leukemia. Leukemia, 2007, 21, 472-479.	3.3	52
115	Response to donor lymphocyte infusions for chronic myeloid leukemia is dose-dependent: the importance of escalating the cell dose to maximize therapeutic efficacy. Leukemia, 2007, 21, 943-948.	3.3	46
116	Mesenchymal stem cells of cord blood origin are effective at preventing but not treating graft-versus-host disease. Leukemia, 2007, 21, 1992-1999.	3.3	167
117	Factors for graft-versus-host disease after donor lymphocyte infusions with an escalating dose regimen: lack of association with cell dose. British Journal of Haematology, 2007, 136, 833-836.	1.2	25
118	The Immunoregulatory Role of Mesenchymal Stem Cells. , 2007, , 35-48.		0
119	Serial measurement of BCR-ABL transcripts in the peripheral blood after allogeneic stem cell transplantation for chronic myeloid leukemia: an attempt to define patients who may not require further therapy. Blood, 2006, 107, 4171-4176.	0.6	119
120	Correction of severe anaemia using immuno-regulated gene therapy is achieved by restoring the early erythroblast compartment. British Journal of Haematology, 2006, 132, 608-614.	1.2	2
121	The role of mesenchymal stem cells in haemopoiesis. Blood Reviews, 2006, 20, 161-171.	2.8	304
122	Characterization and Clinical Application of Human CD34+Stem/Progenitor Cell Populations Mobilized into the Blood by Granulocyte Colony-Stimulating Factor. Stem Cells, 2006, 24, 1822-1830.	1.4	267
123	Hematopoietic and mesenchymal stem cell transplantation in autoimmune diseases. Future Rheumatology, 2006, 1, 179-188.	0.2	0
124	Engraftment of Allogeneic Hematopoietic Stem Cells Requires Both Inhibition of Host-Versus-Graft Responses and â€˜Space' for Homeostatic Expansion. Transplantation, 2005, 79, 1484-1491.	0.5	16
125	Management of chronic myeloid leukaemia in relapse following donor lymphocyte infusion induced remission: a retrospective study of the clinical trials committee of the British Society of Blood & Marrow Transplantation (BSBMT). Bone Marrow Transplantation, 2005, 36, 1065-1069.	1.3	10
126	Reply to â€˜Does post-transplant treatment with imatinib mesylate inhibit graft-versus-leukemia?â€™ by Chunduri et al. Leukemia, 2005, 19, 457-457.	3.3	0

#	Article	IF	Citations
127	Monitoring patients in complete cytogenetic remission after treatment of CML in chronic phase with imatinib: patterns of residual leukaemia and prognostic factors for cytogenetic relapse. Leukemia, 2005, 19, 507-512.	3.3	94
128	HB-EGF/HER-1 signaling in bone marrow mesenchymal stem cells: inducing cell expansion and reversibly preventing multilineage differentiation. Blood, 2005, 106, 59-66.	0.6	210
129	Bone marrow mesenchymal stem cells induce division arrest anergy of activated T cells. Blood, 2005, 105, 2821-2827.	0.6	1,026
130	Minor histocompatibility antigens and stem cell transplantation. Vox Sanguinis, 2004, 87, 11-14.	0.7	8
131	Imatinib inhibits the activation and proliferation of normal T lymphocytes in vitro. Leukemia, 2004, 18, 1332-1339.	3.3	123
132	Adjuvant interleukin-2 therapy for patients refractory to donor lymphocyte infusions. Experimental Hematology, 2004, 32, 218-223.	0.2	37
133	Donor Lymphocyte Infusions for Patients who Relapse After Allogeneic Stem Cell Transplantation for Chronic Myeloid Leukaemia. Leukemia and Lymphoma, 2003, 44, 23-28.	0.6	35
134	Dendritic cells from CML patients have altered actin organization, reduced antigen processing, and impaired migration. Blood, 2003, 101, 3560-3567.	0.6	93
135	Bone marrow mesenchymal stem cells inhibit the response of naive and memory antigen-specific T cells to their cognate peptide. Blood, 2003, 101, 3722-3729.	0.6	1,483
136	Multiparity induces priming to male-specific minor histocompatibility antigen, HY, in mice and humans. Blood, 2003, 102, 388-393.	0.6	115
137	Chronic myeloid leukemia in chronic phase responding to imatinib: the occurrence of additional cytogenetic abnormalities predicts disease progression. Haematologica, 2003, 88, 260-7.	1.7	71
138	Two distinct HLA-A0201â€“presented epitopes of the Wilms tumor antigen 1 can function as targets for leukemia-reactive CTL. Blood, 2002, 100, 3835-3837.	0.6	113
139	Donor lymphocyte infusion for relapsed chronic myelogenous leukemia: prognostic relevance of the initial cell dose. Blood, 2002, 100, 397-405.	0.6	186
140	Imatinib mesylate (STI571) in the treatment of relapse of chronic myeloid leukemia after allogeneic stem cell transplantation. Blood, 2002, 99, 3861-3862.	0.6	78
141	Prognostic factors for acute graft-versus-host disease after donor lymphocyte infusions. Blood, 2002, 100, 2673-2673.	0.6	16
142	Early detection of BCR-ABL transcripts by quantitative reverse transcriptaseâ€“polymerase chain reaction predicts outcome after allogeneic stem cell transplantation for chronic myeloid leukemia. Blood, 2001, 97, 1560-1565.	0.6	154
143	Examination of HY Response: T Cell Expansion, Immunodominance, and Cross-Priming Revealed by HY Tetramer Analysis. Journal of Immunology, 2001, 167, 3756-3764.	0.4	63
144	Cytomegalovirus seropositivity adversely influences outcome after T-depleted unrelated donor transplant in patients with chronic myeloid leukaemia: the case for tailored graft-versus-host disease prophylaxis. British Journal of Haematology, 2001, 112, 228-236.	1.2	101

#	Article	IF	Citations
145	Molecular studies in patients with chronic myeloid leukaemia in remission 5 years after allogeneic stem cell transplant define the risk of subsequent relapse. British Journal of Haematology, 2001, 115, 569-574.	1.2	66
146	Minor antigen solves major problem. Nature Medicine, 2001, 7, 769-770.	15.2	5
147	Immune haemolytic anaemia following T cell-depleted allogeneic bone marrow transplantation for chronic myeloid leukaemia: association with leukaemic relapse and treatment with donor lymphocyte infusions. Bone Marrow Transplantation, 2001, 28, 581-586.	1.3	31
148	Estimating leukemia-free survival after allografting for chronic myeloid leukemia: a new method that takes into account patients who relapse and are restored to complete remission. Blood, 2000, 96, 86-90.	0.6	62
149	Durability of responses following donor lymphocyte infusions for patients who relapse after allogeneic stem cell transplantation for chronic myeloid leukemia. Blood, 2000, 96, 2712-2716.	0.6	243
150	Estimating leukemia-free survival after allografting for chronic myeloid leukemia: a new method that takes into account patients who relapse and are restored to complete remission. Blood, 2000, 96, 86-90.	0.6	2
151	Durability of responses following donor lymphocyte infusions for patients who relapse after allogeneic stem cell transplantation for chronic myeloid leukemia. Blood, 2000, 96, 2712-2716.	0.6	0
152	Donor lymphocyte infusions for relapse of chronic myeloid leukemia after allogeneic stem cell transplant. Experimental Hematology, 1999, 27, 1477-1486.	0.2	116
153	Donor lymphocyte infusions. Current Opinion in Hematology, 1999, 6, 394.	1.2	45
154	Adoptive immunotherapy for relapse of chronic myeloid leukemia after allogeneic bone marrow transplant: equal efficacy of lymphocytes from sibling and matched unrelated donors. Bone Marrow Transplantation, 1998, 21, 1055-1061.	1.3	67
155	Detection of B-Cell Monoclonality in Fine Needle Aspiration by PCR Analysis. Leukemia and Lymphoma, 1998, 29, 179-185.	0.6	33
156	ADOPTIVE IMMUNOTHERAPY FOLLOWING ALLOGENEIC BONE MARROW TRANSPLANTATION. Annual Review of Medicine, 1998, 49, 329-340.	5.0	46
157	4G/5G Polymorphism of PAI-1 Gene Promoter and Fibrinolytic Capacity in Patients with Deep Vein Thrombosis. Thrombosis and Haemostasis, 1998, 80, 956-960.	1.8	94
158	The Kinetics and Extent of Engraftment of Chronic Myelogenous Leukemia Cells in Non-Obese Diabetic/Severe Combined Immunodeficiency Mice Reflect the Phase of the Donorâ€™s Disease: An In Vivo Model of Chronic Myelogenous Leukemia Biology. Blood, 1998, 92, 1390-1396.	0.6	5
159	The Risk of Recurrent Venous Thromboembolism in Patients with an Arg506â†'Gln Mutation in the Gene for Factor V (Factor V Leiden). New England Journal of Medicine, 1997, 336, 399-403.	13.9	385
160	Prevalence of antiâ€FVIII antibodies in severe haemophilia A patients with inversion of intron 22. British Journal of Haematology, 1997, 97, 807-809.	1.2	18
161	The rate and kinetics of molecular response to donor leucocyte transfusions in chronic myeloid leukaemia patients treated for relapse after allogeneic bone marrow transplantation. British Journal of Haematology, 1997, 99, 945-950.	1.2	72
162	CD25-negative hairy cell leukaemia: Intracytoplasmic detection of Tac antigen and interferon-induced surface expression. Journal of Pathology, 1995, 177, 41-47.	2.1	7

#	Article	IF	Citations
163	A Role for Platelet-Derived Growth Factor in Drug-Induced Chronic Ergotism?. Angiology, 1995, 46, 633-636.	0.8	5
164	Marked but Transitory Elevation of Hepatic Transaminases after Subcutaneous Calcium Heparin Administration. Acta Haematologica, 1994, 92, 54-54.	0.7	2
165	Unusual Association of Hairy Cell Leukemia and Monoclonal Large Granular Lymphocyte Proliferation. Leukemia and Lymphoma, 1990, 2, 433-436.	0.6	0
166	Lithium Carbonate Failed to Modify the Neutropenia Associated with Large Granular Lymphocyte Proliferation. Acta Haematologica, 1989, 81, 114-115.	0.7	1
167	Immunologic abnormalities in angioimmunoblastic lymphadenopathy. Cancer, 1987, 60, 2412-2418.	2.0	25
168	The failure of female cells to present in vitro the male H-Y antigen for secondary cytotoxic T-cell responses. Immunogenetics, 1985, 22, 177-181.	1.2	3
169	Molecular Basis of Transplantation. , 0, , 380-389.		0